Skip to main content

Table 4 Treatment and follow-up of 12 cases with major discrepancies

From: Suboptimal concordance in testing and retesting results of triple-negative breast carcinoma cases among laboratories: one institution experience

Case ID Diagnosis Stage Treatment Pathologic response (if NACT) Follow-up year (diagnosis) Impact
1 IDC pT1c N0 Surgery
Adjuvant chemotherapy
Radiation
N/A 4 (free of disease) No hormonal therapy
2 IDC ypT1a N0 NACT
surgery
Adjuvant radiation
Hormone therapy
Partial 3 (free of disease) Hormonal therapy
3 ILC ypT3N3a NACT
surgery
Adjuvant radiation
Partial 3 (developed TN Chest wall recurrence) No hormonal therapy
4 IDC ypT1cN1a NACT
surgery
Adjuvant radiation
Almost complete 3 (free of disease) No hormonal therapy
5 IDC pT1cN0 Surgery
Adjuvant chemotherapy
N/A 3 (free of disease) No hormonal therapy
6 IDC ypT1aN2a NACT
surgery
Adjuvant radiation
Partial 1 (progressive metastatic disease and lost to follow-up) No hormonal therapy
7 IDC cT2N3M1 Palliative chemotherapy (un-resectable disease) N/A 1 (progressive disease and lost to follow-up) No hormonal therapy
8 IDC pT3N0 Surgery
Adjuvant chemotherapy
radiation
N/A 2 (progressive TN disease) No hormonal therapy
(ER, PR, and HER2 repeated at excision were negative)
9 IDC cT2N0 NACT (outside hospital) N/A N/A (lost to follow-up/
transferred care)
 
10 IDC cT2N1M1 Chemotherapy radiation (bone met)   3 (progressive ER+ disease) Hormonal therapy
(Primary breast carcinoma ER: 10%, PR: 0%)
11 IDC ypT2N1 NACT
surgery
Adjuvant radiation
  3 (local recurrence
TN progressive disease)
No hormonal therapy
12 IDC ypT2N1mi NACT
surgery
Adjuvant radiation
  2 (metastasis
progressive disease: ER, PR, HER2 unknown)
No hormonal therapy
  1. ER estrogen receptor, HER2 human epidermal growth factor receptor 2, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, N/A not applicable, NACT neoadjuvant chemotherapy, TN triple negative